This product has no anti-cancer activity in vitro. Once it enters the body, it is hydrolyzed by phosphatase or phosphatase in the liver or tumor, and becomes activated phosphoramide nitrogen mustard to take effect. Its mechanism of action is to cross-link with DNA, inhibit DNA synthesis, and interfere with RNA function. It is a non-specific drug for the cell cycle. This product has a broad anti-tumor spectrum and has inhibitory effects on a variety of tumors.

Extract from the above information

The drug can penetrate into cells and bind to chromosomes. It interferes with DNA and RNA synthesis and protein synthesis by inserting between DNA base pairs; it triggers topoisomerase II to cleave DNA and destroy its tertiary structure; it produces cytotoxic compounds related to oxidation/reduction; and it affects cell membrane function. Doxorubicin is active throughout the cell cycle and is particularly sensitive to rapidly proliferating tissues such as tumor tissues.

Extract from the above information

As a folate reductase inhibitor, this product mainly inhibits dihydrofolate reductase and prevents dihydrofolate from being reduced to physiologically active tetrahydrofolate, thereby hindering the transfer of one-carbon groups in the biosynthesis of purine nucleotides and pyrimidine nucleotides, resulting in the inhibition of DNA biosynthesis. In addition, this product also has an inhibitory effect on thymic nucleotide synthetase, but its effect on inhibiting RNA and protein synthesis is weaker. This product mainly acts on the S phase of the cell cycle and is a cell cycle-specific drug. It also has a delaying effect on cells in the G1/S phase, but its effect on cells in the G1 phase is weaker.